top of page

Our Technology

Increasing Human longevity by actively helping the body heal!

AIMER Nanoparticles Sequence
AIMER Nanoparticles Sequence

We Are Coming


AIMER Nanotherapeutic Platform

(Active Immuno-Modulated Enhanced  Regeneration)

The terms "AIMER", Activated Immuno-Modulated Enhanced Regeneration" and "Programmable Tissue Regeneration" are trademarks of Meridius Bio Corporation.

AIMER Nanoparticles

  • AIMER is a new nanotherapeutic technology that enhances all wound healing strategies and products.

  • AIMER nanoparticles are topically applied or injected locally at the injury site. They are room temperature stable and have a very long (years) shelf life.

  • Animal model data has demonstrated 50-70% reduction in wound healing. Concurrent regenerated normal tissue morphology, reductions in scarring and infections. This includes immune compromised animal models such as diabetes chronic ulcers and radiation burns.

  • Successful Proof-of-Concept in animal models for post-myocardial infarction regeneration, cruciate ligaments, CNS, spinal cord injury muscle and endocrine regeneration.

  • We have 4 issued patents for wound healing tissue regeneration applications using alpha-gal (AIMER) nanoparticles.


AIMER Technology

  • AIMER nanoparticles (NPs) present multiple alpha-gal epitopes on glycolipids, anchored in the nanoparticles wall comprised of phospholipids and cholesterol.

  • There are ~10^14 alpha-gal epitopes per mg alpha-gal NPs.

  • AIMER NPs are topically applied or injected. They are room temperature stable and have a very long (years) shelf life.

  • AIMER NPs can be produced from natural and synthetic alpha-gal glycolipids, phospholipids and cholesterol.

Sign up to receive the first word when we go live.

Thanks for submitting!

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

Investment Risks & Mitigations

Safety & Toxicity - tested in Animal Models, in Humans:

  • Extensive supporting experimental data in Murine and Porcine species (alpha-1,3GT Knockout, human-like).

  • Additionally pre-clinical safety and toxicity studies have been done by others for a human cancer treatment.  In December 2022, they completed a Phase I/IIa trial where it was reported that the study met its primary endpoint for safety and tolerability in humans. Positive secondary endpoint findings related to immune response and markers of clinical efficacy were also reported.

  • Regulatory Risks:

  • Given the extensive experimental and formal testing that has been completed, we believe the AIMER technology represents a significantly de-risked asset.

  • Clinical endpoints for Wound Healing are typically determined in days and weeks, not years.

bottom of page